Abbreviations: SD, standard deviation.
The percentage of patients starting treatment within five days of symptom onset was 57.2 and 86.8% in the Delta and Omicron waves, respectively (p<0.001), and more than half of the patients in the Omicron surge received therapy even within the first three days compared to 27.8% in the Delta period (p=0.001). Patients treated with RDV in the Delta wave were significantly more likely to require tocilizumab (p=0.0357), while dexamethasone was used in a comparative percentage of patients, and baricitinib, administered to single patients, was significantly more common in the Omicron wave (p=0.0472). Low molecular weight heparin at a prophylactic dose was used in a comparable percentage of patients in both waves, while the therapeutic dose was significantly more frequently received by patients in the Omicron wave.